Revenue growth, reimbursement and strategic alliances.
Vijay Aggarwal, Ph.D. has over thirty years of experience in both pharmaceutical services and clinical diagnostics. In addition to serving as Managing Partner of The Channel Group, Dr. Aggarwal provides strategic advisory services to companies with operations or investments in the clinical diagnostics, molecular diagnostic and anatomic pathology sectors. He is also active with several investment banks and angel investment groups in the healthcare market.
Dr. Aggarwal has experience with early stage companies, having served as CEO of Vaxigenix, a pharmaceutical company developing vaccine treatments for colorectal cancer, and as President and CEO of Aureon Laboratories, Inc., a predictive pathology company offering advanced tissue analysis services to practicing physicians and the pharmaceutical industry. His experience with more mature businesses includes service as President of AAI Development Services, Inc., a global contract research and development services company serving the pharmaceutical and biotech industries. Prior to holding that position, Dr. Aggarwal was President of Quest Diagnostic Ventures, where he had responsibility for new technology, new business models, clinical trials testing, and direct–to-consumer strategies. In addition, he served on the Executive Management team of Quest Diagnostics.
Earlier in his career, Dr. Aggarwal held many positions with SmithKline Beecham Clinical Laboratories (“SBCL”), the clinical laboratory operations of SmithKline Beecham plc, including direct responsibility for all of SBCL’s U.S.-based laboratories as Executive Vice President of Laboratories, responsibility for reimbursement as Vice President of Managed Care and several General Management assignments.
With responsibility for businesses that spanned pre revenue to $1.5B in revenues and a wide network of industry contacts, Dr. Aggarwal is frequently sought out by companies that are facing challenges in clinical development, revenue growth, reimbursement, regulatory approval, strategic alliances and corporate development.
Dr. Aggarwal currently serves on the boards of several privately held diagnostic companies, including: Accugenomics, Genisphere, Inc, Moleculera, Inc, and Targeted Diagnostics and Therapeutics, Inc. Dr. Aggarwal earned a Ph.D. in Pharmacology and Toxicology from the Medical College of Virginia.
Related page: Kyle Wilson